AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials
April 8, 2016Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III
AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …
FTC launches tool to help mobile health app developers determine applicable regulations
April 8, 2016Medical Communications, Sales and Marketing FDA, FTC, apps, health, health apps, regulation
The US Federal Trade Commission has created a new web-based tool for developers of health-related mobile apps to help them …
Vectura to get $10 million milestone as Hikma files ANDA for generic copy of GSK’s asthma drug
April 8, 2016Medical Communications, Research and Development, Sales and Marketing
Vectura Group (LSE: VEC) on Friday said it is set to receive $10 million in milestone payments from partner Hikma …
Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar
April 8, 2016Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval
Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route …
Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication
April 7, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
Clinical trials initiated for novel immunotherapy combo for ovarian cancer
April 7, 2016Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx
A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …
Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump
April 7, 2016Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis
Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
UK’s first commercial synthetic biology foundry begins production
April 7, 2016Manufacturing and Production, Research and Development Biological, biologics, foundry, synbicite
SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry. The site provides automated end-to-end design, construction and …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Allergan to partner with Heptares in Alzheimer’s disease collaboration
April 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
Novartis receives EU approval for blood disorder treatment in children
April 7, 2016Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp
Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
5 things to know about the Pfizer/Allergan inversion collapse
April 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million
April 6, 2016Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research
Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
Sepha embarks on a busy Spring of International Exhibitions
April 6, 2016Medical Communications sepha, spring
Pharmaceutical packaging specialist, Sepha Ltd, has sprung into the spring quarter with a number of international exhibitions. Having developed a …
Allergan, Pfizer confirm termination of $160 billion merger
April 6, 2016Business Services, Research and Development, Sales and Marketing
Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country
April 6, 2016Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly
There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay
April 6, 2016Manufacturing and Production, Research and Development
Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer
April 6, 2016Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics
Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
